WO2024210903 - MODIFIED PEPTIDE LIGANDS FOR STABLE DELIVERY OF HIGHLY POTENT PAYLOADS TO TUMORS: METHOD OF MAKING AND USING SAME
National phase entry is expected:
Publication Number
WO/2024/210903
Publication Date
10.10.2024
International Application No.
PCT/US2023/017833
International Filing Date
07.04.2023
Title **
[English]
MODIFIED PEPTIDE LIGANDS FOR STABLE DELIVERY OF HIGHLY POTENT PAYLOADS TO TUMORS: METHOD OF MAKING AND USING SAME
[French]
LIGANDS PEPTIDIQUES MODIFIÉS POUR ADMINISTRATION STABLE DE CHARGES UTILES HAUTEMENT PUISSANTES À DES TUMEURS : PROCÉDÉ DE FABRICATION ET D'UTILISATION ASSOCIÉ
Applicants **
LAMHARZI, Najib
21430 6th Ave W
Bothell, WA 98021, US
Inventors
LAMHARZI, Najib
21430 6th Ave W
Bothell, WA 98021, US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1305 | |
| EPO | Filing, Examination | 5501 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 9405 |
Total: 17224 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The conjugation of luteinizing hormone-releasing hormone analogs (LHRHa) to highly potent payloads via spacers (linear or branched) and cleavable peptidic linkers generate peptide drug conjugates (PDCs) with stable triazole, thioether, oxime or amide bonds. The PDCs target tumor cells that express LHRH receptor (LHRH-R) and release their payloads inside the lysosomes. The PDCs may be used in a method for killing or inhibiting the growth of a tumor cell, especially in late state, highly invasive and aggressive stage IV tumors and in reoccurring tumors.[French]
La conjugaison d'analogues d'hormone de libération d'hormone lutéinisante (LHRHa) à des charges utiles hautement puissantes par l'intermédiaire d'espaceurs (linéaires ou ramifiés) et de lieurs peptidiques clivables génèrent des conjugués de médicament peptidique (PDC) ayant des liaisons triazole, thioéther, oxime ou amide stables. Les PDC ciblent des cellules tumorales qui expriment le récepteur LHRH (LHRH-R) et libèrent leurs charges utiles à l'intérieur des lysosomes. Les PDC peuvent être utilisés dans un procédé pour détruire ou inhiber la croissance d'une cellule tumorale, en particulier dans des tumeurs de stade IV à état tardif, hautement invasives et agressives et dans des tumeurs à récurrence.